Stay updated on Chemotherapy After PD-1/L1 Inhibitors Clinical Trial

Sign up to get notified when there's something new on the Chemotherapy After PD-1/L1 Inhibitors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Chemotherapy After PD-1/L1 Inhibitors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:32:56.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the information related to a clinical trial involving chemotherapy with pembrolizumab after progression with previous PD-1/L1 inhibitors in patients with advanced non-small cell lung cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:16.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for male and female participants aged 20 and above with a histologically confirmed diagnosis of non-small cell carcinoma and other specific health conditions. Previously, this section only mentioned that no information was provided about collaborators.
    Difference
    49%
    Check dated 2024-05-22T21:21:38.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:57:15.000Z thumbnail image

Stay in the know with updates to Chemotherapy After PD-1/L1 Inhibitors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Chemotherapy After PD-1/L1 Inhibitors Clinical Trial page.